Additionally,the dual agonist tirzepatide (targeting GLP-1R and GIPR) was recentlyapproved for the treatment of obesity and type 2 diabetes. Furthermore, thetriple agonist retatrutide (targeting GLP-1R, GIPR, and GCGR) hasshown remarkable effects on weight loss and is currently in advancedclinical trials. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.